Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 7 clients • 7 examiners • 7 art units • 0 of 7 (0%) have an AI response strategy ready
SMITH PATENT, LLC has managed 442 career applications with a focus on the Biotechnology & Pharmaceuticals technology area. The firm maintains a resolved allowance rate of 86.35 percent. This performance is achieved with an average of 3.76 office actions per allowance. These metrics provide a basis for understanding the firm's prosecution history.
Currently, the firm has 7 pending office actions. This volume of work follows a history of 442 career applications. The 86.35 percent resolved allowance rate indicates the firm's results in its technology area. Practitioners can use the 3.76 average office actions per allowance to set expectations for prosecution timelines in Biotechnology & Pharmaceuticals.
The 7 pending office actions represent the firm's current workload. The firm demonstrates experience in its field through its historical record of applications. The average office actions per allowance provides a metric for the effort required to reach a resolution. These data points offer a view of the firm's historical and current prosecution activity for its clients.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (14%) |
| §112 only | 2 (29%) |
| Multi-statute (no §101) | 4 (57%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHOI, PETER Y | 1 | 20.4% | +32.5% |
| HOLLAND, PAUL J | 1 | 57.3% | +64.7% |
| MUTCHLER, CHRISTOPHER JOHN | 1 | 55.7% | +22.7% |
| FAUST, AMBER KATHLEEN | 1 | 61.1% | +53.6% |
| REDDIG, PETER J | 1 | 58.0% | +40.2% |
| MERCIER, MELISSA S | 1 | 72.1% | +5.8% |
| METCALF, MATTHEW CURRAN | 1 | 37.5% | +71.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18818331 | Composition Comprising an Alkyd Resin | CHOI, PETER Y | — |
| 18701828 | AQUEOUS FORMULATIONS OF AN ANTI-CD22 ANTIBODY AND USES THEREOF | FAUST, AMBER KATHLEEN | — |
| 18571406 | APPLICATION OF HCMV GP34- AND GP68-SPECIFIC ANTIBODIES AND FRAGMENTS THEREOF FOR PREVENTION, THERAPY AND DIAGNOSTICS OF HCMV DISEASE | REDDIG, PETER J | — |
| 18044948 | CHIMERIC SENSOR PROTEIN AND METHODS OF USE THEREOF | METCALF, MATTHEW CURRAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18657444 | Methods, Systems, Devices and Components for the Treatment of Stroke in a Patient with Interferential Cranial Electrical Stimulation | MUTCHLER, CHRISTOPHER JOHN | 31d overdue |
| 18818331 | Composition Comprising an Alkyd Resin | CHOI, PETER Y | — |
| 18711814 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF PREGABALIN INTERMEDIATES | HOLLAND, PAUL J | — |
| 18701828 | AQUEOUS FORMULATIONS OF AN ANTI-CD22 ANTIBODY AND USES THEREOF | FAUST, AMBER KATHLEEN | — |
| 18571406 | APPLICATION OF HCMV GP34- AND GP68-SPECIFIC ANTIBODIES AND FRAGMENTS THEREOF FOR PREVENTION, THERAPY AND DIAGNOSTICS OF HCMV DISEASE | REDDIG, PETER J | — |
| 18044948 | CHIMERIC SENSOR PROTEIN AND METHODS OF USE THEREOF | METCALF, MATTHEW CURRAN | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Munditia Technologies GmbH | 1 |
| Enzymaster (Ningbo) Bio-Engineering Co., Ltd. | 1 |
| Makous Research, LLC | 1 |
| Sinomab Bioscience Limited | 1 |
| UNIVERSITY OF RIJEKA FACULTY OF MEDICINE | 1 |
| Luye Pharma | 1 |
| Universitaet Leipzig | 1 |
| Art Unit | Apps |
|---|---|
| 1786 | 1 |
| 1656 | 1 |
| 3796 | 1 |
| 1643 | 1 |
| 1646 | 1 |
| 1615 | 1 |
| 1647 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18818331 | Composition Comprising an Alkyd Resin | Munditia Technologies GmbH | CHOI, PETER Y | 1786 | §102§103§112 | Non-Final OA | — | Pending | Aug 28, 2024 |
| 18711814 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF PREGABALIN INTERMEDIATES | Enzymaster (Ningbo) Bio-Engineering Co., Ltd. | HOLLAND, PAUL J | 1656 | §112 | Non-Final OA | — | Pending | May 20, 2024 |
| 18657444 | Methods, Systems, Devices and Components for the Treatment of Stroke in a Patient with Interferential Cranial Electrical Stimulation | Makous Research, LLC | MUTCHLER, CHRISTOPHER JOHN | 3796 | §103 | Final Rejection | 31d overdue | Pending | May 07, 2024 |
| 18701828 | AQUEOUS FORMULATIONS OF AN ANTI-CD22 ANTIBODY AND USES THEREOF | Sinomab Bioscience Limited | FAUST, AMBER KATHLEEN | 1643 | §102§103 | Non-Final OA | — | Pending | Apr 16, 2024 |
| 18571406 | APPLICATION OF HCMV GP34- AND GP68-SPECIFIC ANTIBODIES AND FRAGMENTS THEREOF FOR PREVENTION, THERAPY AND DIAGNOSTICS OF HCMV DISEASE | UNIVERSITY OF RIJEKA FACULTY OF MEDICINE | REDDIG, PETER J | 1646 | §102§103§112 | Non-Final OA | — | Pending | Dec 18, 2023 |
| 17794886 | TRANSDERMAL THERAPEUTIC SYSTEM COMPRISING THE INGREDIENT ROTIGOTINE AND AT LEAST ONE NON-AMINE-RESISTANT SILICONE ADHESIVE | Luye Pharma Switzerland AG | MERCIER, MELISSA S | 1615 | §112 | Final Rejection | 58d overdue | Pending | Mar 29, 2023 |
| 18044948 | CHIMERIC SENSOR PROTEIN AND METHODS OF USE THEREOF | Universitaet Leipzig | METCALF, MATTHEW CURRAN | 1647 | §103§112 | Non-Final OA | — | Pending | Mar 10, 2023 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial86.3% of resolved applications prosecuted by Smith Patent, LLC were allowed, across 442 applications in USPTO records.
3.76 office actions per allowed application on average.
7 pending office actions as of October 2026, for 7 clients, before 7 examiners in 7 art units.
